PMA P100006S005

Device
AUGMENT INJECTABLE
Applicant
Biomimetic Therapeutics, LLC
PMA number
P100006
Supplement
S005
Product code
NOX
Decision date
2018-06-12
Classification
Filler, Bone Void, Synthetic Peptide
Generic name
Filler, bone void, synthetic peptide
Approval order statement
Approval for AUGMENT Injectable. This combination product is indicated for use as an alternative to autograft in arthrodesis (i.e., surgical fusion procedures) of the ankle (tibiotalar joint) and/or hindfoot (including subtalar, talonavicular, and calcaneocuboid joints, alone or in combination), due to osteoarthritis, post- traumatic arthritis, rheumatoid arthritis, psoriatic arthritis, avascular necrosis, joint instability, joint deformity, congenital defect, or joint arthropathy in patients with preoperative or intraoperative evidence indicating the need for supplemental graft material.
Summary
<a href="http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100006S005B.pdf" target="_new">Summary of Safety and Effectiveness</a>

Current openFDA PMA Record#

Device
AUGMENT INJECTABLE
Applicant
Biomimetic Therapeutics, LLC
PMA number
P100006
Supplement
S005
Product code
NOX
Generic name
Filler, bone void, synthetic peptide
Decision date
2018-06-12
Decision code
APPR
Date received
2016-10-31
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Approval order statement
Approval for AUGMENT Injectable. This combination product is indicated for use as an alternative to autograft in arthrodesis (i.e., surgical fusion procedures) of the ankle (tibiotalar joint) and/or hindfoot (including subtalar, talonavicular, and calcaneocuboid joints, alone or in combination), due to osteoarthritis, post- traumatic arthritis, rheumatoid arthritis, psoriatic arthritis, avascular necrosis, joint instability, joint deformity, congenital defect, or joint arthropathy in patients with preoperative or intraoperative evidence indicating the need for supplemental graft material.